Director Kathleen LaPorte receives 9,810 Q32 Bio (QTTB) stock options

Rhea-AI Filing Summary

Q32 Bio Inc. director Kathleen LaPorte received a grant of stock options covering 9,810 shares of common stock at an exercise price of $12.64 per share. These options vest in full on the earlier of June 12, 2027 or the company’s next annual stockholder meeting, subject to her continued service, and represent her entire reported option position in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAPORTE KATHLEEN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,810	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,810 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 9,810 shares Exercise price: $12.64 per share Shares underlying options: 9,810 shares +2 more

5 metrics

Option shares granted 9,810 shares Stock Option (Right to Buy) grant to director

Exercise price $12.64 per share Strike price for the stock options

Shares underlying options 9,810 shares Underlying common stock for the option award

Total options after grant 9,810 options Total derivative position following transaction

Option expiration June 11, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), exercise price, vest and become exercisable, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "12.6400""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"shares underlying this option shall vest and become exercisable in full"

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 04:31 PM Accepted by SEC EDGAR 06/16/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAPORTE KATHLEEN

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		9,810		(1)	06/11/2036	Common Stock	9,810	$0	9,810	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Q32 Bio (QTTB) director Kathleen LaPorte report in this Form 4?

Kathleen LaPorte reported receiving a grant of stock options for 9,810 shares of Q32 Bio common stock. The options were granted at an exercise price of $12.64 per share as part of her compensation as a director.

How many Q32 Bio shares are covered by the new stock options?

The new stock option grant covers 9,810 shares of Q32 Bio common stock. This entire amount is reported as held following the transaction, indicating the options were newly awarded rather than exercised from an existing position.

What is the exercise price and expiration date of Kathleen LaPorte’s Q32 Bio options?

The options have an exercise price of $12.64 per share and expire on June 11, 2036. This means she can choose to purchase shares at $12.64 any time after vesting until that expiration date, subject to plan terms.

When do Kathleen LaPorte’s Q32 Bio stock options vest?

The options vest and become exercisable in full on the earlier of June 12, 2027, or the date of Q32 Bio’s next annual stockholder meeting. Vesting is conditioned on her continued service as a director through that vesting date.

Does this Form 4 show Kathleen LaPorte buying or selling Q32 Bio stock in the market?

No, the Form 4 reports a compensatory grant of stock options rather than an open-market purchase or sale. The transaction code "A" reflects a grant or award, with no common shares bought or sold in this filing.